Haemonetics (NYSE:HAE) & BZAM (OTCMKTS:BZAMF) Head-To-Head Comparison

BZAM (OTCMKTS:BZAMF) and Haemonetics (NYSE:HAE) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

Analyst Recommendations

This is a breakdown of recent recommendations for BZAM and Haemonetics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BZAM	0	0	0	0	0.00
Haemonetics	1	3	7	1	2.67

Haemonetics has a consensus price target of $84.40, suggesting a potential upside of 28.20%. Given Haemonetics’ stronger consensus rating and higher possible upside, analysts clearly believe Haemonetics is more favorable than BZAM.

Profitability

This table compares BZAM and Haemonetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BZAM	N/A	N/A	N/A
Haemonetics	12.67%	27.22%	9.52%

Institutional & Insider Ownership

0.0% of BZAM shares are owned by institutional investors. Comparatively, 99.7% of Haemonetics shares are owned by institutional investors. 8.7% of BZAM shares are owned by insiders. Comparatively, 1.8% of Haemonetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares BZAM and Haemonetics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BZAM	N/A	N/A	N/A	($0.27)	N/A
Haemonetics	$1.36 billion	2.26	$167.68 million	$3.42	19.25

Haemonetics has higher revenue and earnings than BZAM. BZAM is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Summary

Haemonetics beats BZAM on 10 of the 11 factors compared between the two stocks.

About BZAM

BZAM Ltd. operates as a cannabis producer with a focus on branded consumer goods. Its brands include the BZAM, TGOD, ness, Highly Dutch Organic, and TABLE TOP, as well as Dunn Cannabis, FRESH, and Wyld partner brands. The company operate facilities in British Columbia, Alberta, Ontario, and Quebec, as well as retail stores in Winnipeg, Manitoba and Regina, Saskatchewan. The company was formerly known as The Green Organic Dutchman Holdings Ltd. and changed its name to BZAM Ltd. in February 2023. The company was incorporated in 2016 and is headquartered in Vancouver, Canada.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.